As per recent multinational, randomized, double-blind trial published in Mabs Journal, the rituximab (RTX) and its biosimilar CT-P10 appeared to have identical immunogenicity, pharmacodynamics, safety and efficacy measures in managing rheumatoid arthritis (RA). Park W and colleagues conducted the trial within 372 RA patients, out of which 161 patients allocated to CT-P10 group and 211 to RTX group. The change in primary efficacy endpoint from baseline to week 24 was measured through Disease Activity Score 28 (by using joints-C-reactive protein). The AUC from time zero to last measurable concentration, from time zero to infinity and maximum level after two infusions were used to measured co-primary pharmacokinetic endpoints. The safety, immunogenicity and pharmacodynamics were also determined.
According to a recent meta-analysis, Baricitinib, a JAK 1 and 2 inhibitor has proven to manage rheumatoid arthritis (RA) effectively but with no significant safety concerns. JAK (Janus kinases), play an important role in RA pathogenesis and Baricitinib, therefore, plays a crucial role in RA control. There's no question regarding Baricitinib efficacy; however comprehensive efficacy evaluation was still to be assessed.
The recent strategy for rheumatoid arthritis (RA) management mainly focuses on achieving clinical remission. After the remission is attained and sustained over time, the better efficient strategy is dose optimization. The recent study published in Rheumatology International explained the results of dose optimization after 2 years of follow-up in patients with RA treated with biological therapy and identifies predictive variables of response.
A recent study by Kumar et al, published in Current Orthopaedic Practice found methotrexate (MTX) as a safe and effective choice of treatment among rheumatoid arthritis (RA) patients.
A recent study published in Nutritional Neuroscience has revealed that intake of omega-3 fatty acid leads to a significant reduction in the duration of a migraine attacks.
- 1 of 175